In Kenya, a static cohort modelling study evaluated 12 HPV vaccination policy scenarios to inform the country’s cervical cancer elimination trajectory toward 2030. A prompt switch to a single-dose strategy combined with rapid coverage scale-up would avert an additional 249,700 DALYs compared with the current two-dose programme at approximately 50% coverage, while simultaneously reducing both […]
Topic: Financing
Expanding HPV vaccine Programs to Older Adolescent Girls or Young Boys: Immunization Stakeholder Perspectives in 11 Low- and Middle-Income Countries
Semi-structured interviews with 22 national immunization program managers and advisors across 11 LMICs conducted between May and August 2025 examined stakeholder perspectives on expanding HPV vaccination to older adolescent girls (15–18 years) and young boys (9–14 years). Slightly more stakeholders prioritized older girls, citing continued vaccine effectiveness post-sexual debut, independent health-seeking capacity, and evidence from […]
Financing Of Human Papillomavirus Vaccination In Africa: A Scoping Review
A scoping review of 27 studies across sub-Saharan Africa found that approximately 68% of countries rely on Gavi donations — often supplemented by the Gates Foundation, WHO, or other donors — as their primary HPV vaccine financing mechanism, with financial delivery costs ranging from US$0.27 to US$19.76 per dose depending on country, delivery modality, and […]
Resource Mobilization and Financial Sustainability: Q&A Session
This Q&A addressed private sector engagement, civil society advocacy across government transitions, Kenya’s Gavi re-entry, and South Africa’s Mother-Daughter campaign. Zimbabwe framed HPV as a community protection investment to attract private sector support; Kenya confirmed a 2028 target for first Kenya BioVax doses. Kenya’s return to the Gavi preparatory phase followed a GNI threshold review […]
Resource Mobilization and Financial Sustainability: After Gavi: South Africa’s experience crafting a sustainable HPV vaccination program
In South Africa, HPV vaccination has been fully domestically financed since 2014 through a National Treasury conditional grant — without Gavi support — with provincial allocations rising from R49 million in 2024/25 to a projected R72 million in 2026/27. The programme transitioned to a single-dose schedule from 2023 and expanded to private and independent schools […]
Resource Mobilization and Financial Sustainability: Financial sustainability for HPV vaccination – Zimbabwe
In Zimbabwe, HPV vaccination was introduced nationally in 2018 targeting Grade 5 girls, with initial financing largely provided by Gavi and government co-financing covering procurement and delivery. To sustain the programme amid competing health priorities and fiscal constraints, Zimbabwe has pursued a multi-pronged financing and integration strategy. Key steps include embedding a dedicated HPV budget […]
Resource Mobilization and Financial Sustainability: Financial sustainability for HPV vaccination – Malawi
In Malawi, financial sustainability for HPV vaccination is pursued against a backdrop of significant programmatic complexity and recurrent health emergencies, including COVID-19, polio, cholera outbreaks, and cyclone-related displacement. Cervical cancer is the leading cause of cancer death among women aged 15–49 in Malawi, with an age-standardised incidence of 67.9 per 100,000 women per year and […]
Resource Mobilization and Financial Sustainability: Common challenges in preparing for the Gavi transition – Cote d’Ivoire
In Côte d’Ivoire, the transition away from Gavi financing represents one of the most significant programmatic and financial challenges facing the national immunization programme. Having benefited from Gavi support since 2001, the country entered the accelerated transition phase in late 2022, with a target of full self-financing by 2030. This transition implies a more than […]
Resource Mobilization and Financial Sustainability: Common challenges in preparing for the Gavi transition – Kenya
In Kenya, sustaining HPV vaccination within a life-course immunization framework has become an increasingly urgent policy priority as the country navigates its transition away from Gavi support. Kenya has partnered with Gavi since 2001 — receiving over US$940 million in cumulative support — and introduced HPV vaccination into the routine schedule in 2019; it entered […]
Panel Discussion on funding and financial sustainability
Global partners converged on a shared concern: development assistance for health is projected to fall by nearly 50% between 2021 and 2030, placing acute pressure on African countries where external funding covers more than a third — and in some cases more than half — of health expenditures. Gavi reaffirmed its commitment to HPV vaccination, […]